News

2023-05-31

Redwood Pharma presents positive results from a clinical study with RP501 against dry eye

2023-03-17

Redwood Pharma completes recruitment for clinical trial with RP501 for dry eye

2023-01-24

Redwood Pharma takes important steps towards the commercial production of its dry eye product

2022-12-15

Redwood Pharma enters partnership with Nextec medical in preparation for European market clearance of RP501

2022-10-03

Redwood Pharma to present at AKTIEPORTFÖLJEN LIVE SVERIGE in Stockholm on 11th of Oct. 2022 at 14:45

2022-09-08

Redwood Pharma to present at BioStock Investor Meeting in Stockholm on 14th of Sep. 2022

2022-06-03

Redwood Pharma CEO Martin Vidaeus to present at BioStock Life Science Spring Summit

2022-05-16

CEO Presentation at the Annual General Meeting of Redwood Pharma on May 10, 2022 

2022-05-10

Redwood Pharma AB (publ) Quarterly report January–March 2022

2022-05-05

The first patient has started Redwood Pharma’s RP501 treatment for dry eye

2022-05-02

Redwood Pharma to present at the BioStock Life Science Summit in Lund and Stockholm on 8-9 June 2022

2022-03-28

Redwood Pharma receives approval from the Austrian drug authority to start RP501 clinical trial

2022-03-25

Dry Eye FACTS: first line therapies are tried by nearly all sufferers

2022-03-11

Breaking ground with a novel first line dry eye therapy

2022-02-16

Redwood Pharma AB (publ) Year-end report 2021

2022-02-07

Redwood Pharma receives approval from an Austrian ethics committee for start of a clinical trial of RP501

2022-01-24

Redwood Pharma to attend the ARVO annual meeting and BIO-Europe (Fall) in 2022

2021-12-16

RP501 represents an extension into the medical technology arena for Redwood Pharma

2021-10-25

Accelerating development of RP501 first-line therapy for dry eye disease

2021-08-27

Redwood Pharma AB (publ) Quarterly report January–June 2021

2021-03-22

Phase II results published in medical journal and Redwood Pharma to present poster at medical meeting

2021-02-11

Redwood Pharma will receive approximately SEK 34.2 million through a heavily oversubscribed rights issue

2021-01-20

Redwood Pharma to provide digital presentations in connection with the rights issue

2021-01-18

Redwood Pharma announces intention to move to Nasdaq First North Growth Market stock exchange

2020-12-29

Supplementary analyses to topline Phase II results reveal additional RP101 clinical strengths

2020-10-12

Redwood Pharma to present at Aktiespararnas Stora Aktiedagen Digitalt in Stockholm on November 30, 2020

2020-10-09

RP501: Redwood Pharma makes official name for mild dry eye therapeutic development program

2020-09-08

Redwood Pharma launches new development program for mild dry eye based on its proprietary IntelliGel platform

2020-08-28

Quarterly Report January–June 2020

2020-07-23

New patent for the use of estrogens in the treatment of DED to be issued in the US

2020-06-22

Video interview with CEO Martin Vidaeus – Positive Redwood Pharma status

2020-06-18

Redwood Pharma secures bridge financing and issues warrants

2020-05-18

Redwood Pharma will receive approximately SEK 2.1 million

2020-05-11

Quarterly report January – March 2020

2020-03-12

Live Webcast of the announcement of RP101 Phase II clinical results

2020-03-12

RP101 Phase II clinical results

2020-02-28

Redwood Pharma to present at BIO-Europe Spring

2020-02-14

Redwood Pharma AB (publ) Year-end report 2019

2020-02-10

Patent to be granted in China regarding IntelliGel

2019-12-05

Video presentation (ENG) of clinical status of RP101 by CEO Martin Vidaeus

2019-11-27

Redwood Pharma arranging partnering meetings during JPMorgan Healthcare Conference 2020 in San Francisco

2019-11-19

Redwood Pharma AB Quarterly Report January – September 2019

2019-11-18

Redwood Pharma to present at BioStock Live in Stockholm on December 3, 2019

2019-11-12

Last patient completes treatment in RP101 Phase II clinical trial

2019-10-25

Redwood Pharma to attend BIO-Europe Nov. 10-12 in Hamburg

2019-08-13

Redwood Pharma to present at BioStock Live in Stockholm on August 27, 2019

2019-08-05

Last patient recruited in Redwood Pharma Phase II trial

2019-06-19

Update regarding financial situation

2019-06-18

Update regarding RP101 Phase II trial

2019-02-11

Redwood Pharma to Attend BIO-Europe 2019, Mar. 25 – 27 in Vienna for Partnering Discussions

2019-02-04

First patient treated in Redwood Pharma Phase II study

2019-01-07

Redwood Pharma receives its third and last national approval

2018-12-14

Redwood Pharma receives approval from another drug authority – the Austrian

2018-11-12

Redwood Pharma initiates clinical trial

2018-10-02

New patent for IntelliGel on the way in the EU

2018-09-18

Redwood Pharma to Attend BIO-Europe 2018, Nov. 5 – 7 in Copenhagen for Partnering Discussions

2018-09-10

Redwood Pharma to present at Nordic Life Science Days in Stockholm on September 11, 2018

2018-08-29

Interim Report January – June 2018

2018-08-21

Come meet us when Redwood Pharma presents

2018-07-09

Redwood Pharma has submitted an application for the start of clinical trial

2018-06-13

Video Presentation (ENG) by Redwood Pharma June 11, 2018

2018-05-30

Redwood Pharma to present at NLSDays in Stockholm, Sep. 10-12, 2018

2018-04-26

Redwood Pharma’s new rights issue oversubscribed

2018-03-15

Redwood Pharma to execute New Rights Issue and takes important step in securing further financing

2018-03-08

Redwood Pharma acquires intellectual property rights

2018-02-26

Asian Pharmaceutical Firm to Evaluate IntelliGel®

2018-02-26

Positive meeting with Medical Products Agency prior to clinical Phase II trial

2018-02-23

Additional US patent to be granted regarding IntelliGel

2018-01-22

Redwood Pharma to Attend BIO-Europe 2018, Mar. 11 – 14 in Amsterdam for Partnering Discussions

2017-12-04

Interview with CEO: Development throught toxicology and safety studies

2017-11-28

Redwood Pharma starts production of RP101 for clinical trials

2017-11-20

Toxicology and Safety Studies are Successfully Completed

2017-09-20

Redwood Pharma to Attend Bio-Europe 2017, Nov. 6 – 8 in Berlin for Partnering Discussions

2017-09-01

Redwood Pharma enters into agreement with CRO for clinical trial

2017-06-02

Redwood Pharma begins production of active ingredient in RP101 for Phase II studies

2017-03-15

Redwood Pharma initiates toxicological safety studies

2017-03-02

New US patent approved

2017-02-15

Redwood Pharma AB (publ) End of Year Report 2016

2017-02-13

Eye expert to support Redwood Pharma

2017-01-16

Redwood Pharma has developed a process for manufacture of the drug RP101 for coming safety studies

2016-12-21

Development of Redwood Pharma’s RP101 ophthalmic therapy continues according to plan along with value-enhancing networking

2016-11-08

Redwood Pharma AB (publ) to present at Aktiespararna conference in Örebro on November 19, 2016

2016-10-07

Redwood Pharmas IntelliGel drug delivery platform demonstrates positive results in in vitro test

2016-09-20

Redwood Pharma AB appoints Ulf Björklund as Chief Medical Officer

2016-09-16

Market Trends Highlighted in Tear Film and Ocular Surface (TFOS) Conference in Montpellier Confirm Need for Redwood Pharmas Dry Eye Therapy

2016-08-30

Japanese patent granted for IntelliGel platform

2016-08-11

Redwood Pharma to present at French-Swedish Life Science Day 2016

2016-08-09

Redwood Pharma to attend leading conference on ocular tear film science

2016-07-11

Redwood Pharma attending OIS-ASRS Conference in San Francisco

2016-06-07

Redwood Pharma to Present at BIO 2016 in San Francisco

2016-02-23

Redwood Pharma raises SEK 6.6 million in private placement

2015-06-24

Redwood Pharma licenses novel hydrogel drug delivery technology from Broda Technologies